Pharmacoinformatics approaches are widely used in the field of drug discovery as it saves time, investment and animal sacrifice. In the present study, pharmacophore based virtual screening was adopted to identify potential HIV-protease ligand as anti-HIV agents. Pharmacophore is the 3D orientation and spatial arrangement of functional groups that are critical for binding at the active 
Introduction
Acquired immunodeficiency syndrome (AIDS) is an epidemic disease with an estimated two million deaths each year [1] and remains one of the world's most significant public health challenges, predominantly in low-and middle-income countries. The causative agent of the AIDS is human immunodeficiency virus type -1 (HIV-1) [2] [3] [4] [5] which is characterized by extensive and dynamic genetic diversity [6] that has implications for the understanding of viral transmission, pathogenesis and diagnosis, and strongly influences strategies for vaccine development. The HIV polyprotein precursor is encoded by relatively simple genomes consisting of gag, pol and env open reading frames. The gag gene encodes the structural capsid, nucleocapsid, and matrix protein; env undergoes multiple alternative splicing events to regulatory protein; while, pol encodes essential viral enzymes necessary for viral replication. The HIV-1 protease receptor (HIV-1 PR) is an aspartyl protease that is required for proteolytic processing of the gag and gag-pol polyprotein precursors to yield the viral enzyme and structural proteins and is absolutely indispensible for proper viron assembly and maturation [7] . For this reason this protein is one of the major targets for the design of anti-HIV inhibitors [8] for the treatment of AIDS due to its critical role in virus maturation and replication. HIV-1 PR contains a homodimeric C-2 symmetric structure and each monomer contributes one catalytic aspartic residue along with threonine and glycine residues which are flexible and a flap that favors the binding of substrate and inhibitors. The highly active antiretroviral therapy (HAART) and protease inhibitors (PIs) along with reverse-transcriptase inhibitors have resulted in the unprecedented success of HIV/AIDS chemotherapy [9] [10] [11] [12] . However owing to the rapid emergence of drug-resistant HIV-1 variants and transmission of these resistant viral strains along with the adverse side effects of currently used HIV-1 PIs, are remain critical factors that limiting the clinical effectiveness of HAART [13] [14] [15] . Numerous groups worldwide have developed HIV-1 protease inhibitors, showing excellent antiviral profiles [16] [17] [18] [19] [20] [21] [22] . Up to now, some clinically approved HIV-1 protease inhibitors including atazanavir, indivanir, nelfinavir and sequinavir are available in the market for HIV treatment but they are very peptide-like and have poor bio-availability. Therefore to overcome these problems, there is a need for the development of new PIs with improved activity against drug resistant variants and excellent pharmacokinetic and safety profiles. The pharmacoinformatics approaches including structure activity relationship (SAR), pharmacophore, virtual screening and molecular docking have become pivotal techniques in the pharmaceutical industry for lead discovery. Many groups have applied the pharmacoinformatics approaches to identify inhibitors [23] [24] [25] [26] [27] [28] [29] against HIV protease. Hence the current study explores the binding preferences of the inhibitory molecules of HIV protease in terms of space modelling study and virtual screening along with molecular docking.
A pharmacophore defined as ensemble of steric and electronic features that is required to ensure optimal supra-molecular interactions with a specific biological target and to trigger (or block) its biological response [30] . It also can be stated that the pharmacophore concept is based on the kinds of interaction observed in molecular recognition, i.e., hydrogen bonding, charge, and hydrophobic interaction. The pharmacophore features: hydrogen bond acceptor (HBA) and donor (HBD), hydrophobic (H) and aromatic ring (R) were found to be the key features associated with the selectivity and potency of HIV protease inhibitors. The pharmacophore model can be used in virtual screening to identify potential molecules, predict the activity of the newly synthesized compound before animal experiment; or understand the possible mechanism of action [31, 32] . In this study, an attempt was made to identify the pharmacophore hypothesis using the HypoGen algorithm [33] based on key chemical features of HIV-protease inhibitors with inhibition constant covering a satisfactory wide range of magnitude. The model was validated using several statistical approaches including Fischer's randomization and test set prediction. The validated model was utilized for the virtual screening to select the virtual hits from structural database. The molecular docking study was also performed to elucidate the binding interactions and preferred orientation of proposed potential molecules. The significance of the work is clearly reflected by the identification of seven potent lead molecules as protease inhibitors. Among these seven potential HIV-protease ligand one compound is reportedly confirmed as an active anti-HIV agent, thus validating the approach.
Materials and methods
The pharmacophore space modelling study is one of the most widely used and versatile techniques to discover novel scaffolds for various targets. Mainly, two types of pharmacophore modelling approaches can be used and adopted for searching novel active scaffolds, ligand-based and structure-based. In the present research ligand-based pharmacophore modelling approach was considered for a set of HIV protease inhibitors with inhibitory constant (K i ).
The Discovery Studio 3.5 (DS) [34] was used for the 3D QSAR pharmacophore, virtual screening and molecular docking studies. The DS is commercially available software containing several module packages and widely used in the pharmacoinformatics drug discovery [35] [36] [37] [38] . The 3D QSAR Pharmacophore Generation module enables the use of structure and activity data for a set of potential HIV-protease ligand to create hypotheses. Two algorithms, HypoGen and HipHop are used for ligand-based pharmacophore modelling. The HypoGen allows identification of hypotheses that are common to the 'active' compounds of training set but not present in the 'inactive' compounds, whilst HipHop identifies hypotheses present both in 'active' and 'inactive' compounds.
In the present work the HypoGen algorithm was used to generate the hypotheses. 
Dataset
A dataset of 129 HIV protease inhibitors [39] [40] [41] were collected from literature. The experimental K i values were determined by the same group of authors using fluorescence resonance energy transfer (FRET) method. The whole dataset was divided into training and test set compounds for pharmacophore model generation and validation of generated model respectively. The molecules of the dataset have a wide range of K i , from 0.0008 to 237.8 nM. The whole dataset was divided into three categories based on their activities values; highly active (K i < 1.000 nM, +++), moderately active (1.000 ≤ K i < 66.000 nM, ++) and least active (K i ≥ 66.000 nM, +). To select the training set for pharmacophore model in DS basic guidelines laid down by Li et al. [42] were followed. The guidelines are a) molecules should be selected to provide clear and concise information including structure features and activity range. b) a minimum of 16 diverse molecules for training set should be considered to ensure the statistical significance and avoid chance correlation. c) the training set must include the most and the least active molecules. d) the biological activity data of the molecules should have spanned at least 4 orders of magnitude. Based on the above criteria 30 compounds were selected as training set (n tr = 30, Figure 1 ) and the remaining 99 compounds (Table S1 in Supplementary file) were considered as test set (n ts ) compounds used for assessing the performance of pharmacophore model. The information concerning the structure and the biological activity of test set compounds is provided in the supplementary information, while all the data regarding the training set molecules are reported in Figure 1 . The three-dimensional coordinates of the compounds were generated using the 2D/3D visualizer [34] of DS. For each compound, the geometries were corrected, atoms were typed and energy minimization was performed based on the modified CHARMm force field [43, 44] . The various protocols in the molecular modelling package, DS were utilized for 3D-QSAR modelling, virtual screening and molecular docking studies.
Pharmacophore model generation
The pharmacophore model was developed using 3D QSAR Pharmacophore Model Generation module of DS. The training set molecules were considered to generate conformation by Cat-Conf program of the DS software package. The BEST method was applied during generation of multiple acceptable conformations which provides complete and improved coverage of conformational space by performing a rigorous energy minimization and optimizing the conformations in both torsional and Cartesian space using the poling algorithm [45] . The algorithm best conformer generation considers the arrangement in space of chemical features rather than simply the arrangement of atoms [46] . The Feature mapping was used to predict the favourable features for the highly active compounds of the dataset. Mapped features were considered as input features for model generation.
Followed by the conformer generation, the algorithm also considers chemical features and conformers, and operates in two modes: HipHop and HypoGen. HipHop generates pharmacophore models using active compounds only, whereas HypoGen takes activity data into account and uses both active and inactive compounds in an attempt to identify a hypothesis that is common among the active compounds but not in the inactive compounds [46] . It builds top ten scoring hypothesis models with consideration of the training set, conformational models and chemical features by three steps: a constructive step, a subtractive step and an optimization step [47] . The constructive step generates hypotheses that are common among the most active compounds, while in subtractive step, the hypotheses that fit to the inactive compounds are removed. Finally, the optimization step attempts to improve the score of the remaining hypotheses by applying small perturbation [46, 48] .
The best hypothesis was selected based on the high correlation coefficient (R), low root mean square deviation (rmsd), cost function analysis and good predictive ability.
Validation of pharmacophore model
Validation is an essential step of any in-silico model to judge the predictivity and applicability as well as robustness. In the current study, the developed pharmacophore hypotheses were validated by four different methods, (1) internal validation, (2) cost function analysis, (3) Fischer's randomization test and (4) test set prediction.
Internal validation
The best model was validated internally using the leave-one out (LOO) cross-validation method. In this procedure, one compound was randomly deleted from training set in each cycle and model regenerated using the rest of the compounds with the same parameters used in original model. The new generated model was used to predict the activity of deleted compound. The procedure was continued until all molecules of the training set were deleted and activity predicted. The LOO crossvalidated correlation coefficient (Q 2 ) and error of estimation (se) were calculated based on predicted activity of training compounds as explained above. High Q 2 (>0.5) and low se (<0.5) explained better predictive ability [49] .
Further to confirm the good predictive ability of the training set compounds, the modified r 
Cost function analysis
The statistical parameters employed for hypothesis generation were spacing, uncertainty, and weight variation. Spacing is a parameter representing the minimum inter-features distance that may be allowed in the resulting hypothesis. The weight variation is the level of magnitude explored by the hypothesis in where each feature signifies some degree of magnitude of the compound's activity. This varied in some cases from 1 to 2. In other cases, the default value of 0.3 is generally considered. The uncertainty parameter reflects the error of prediction and denotes the standard deviation of a prediction error factor called the error cost. In the present work, values of 1.5 to 3.0 were considered as the uncertainty parameter. The total cost function is minimized encompassing three terms, viz., weight cost, error cost, and configuration cost. Weight cost is the value that increases as the weight variation in the model deviates from the input weight variation value. The deviation between the estimated activity of the molecule in the training set and their experimentally determined value is the error cost. A fixed cost depends on the complexity of the hypothesis space being optimized and is also denoted as the configuration cost. The configuration cost is equal to the entropy of hypothesis space and should have a value <17 for a good pharmacophore model. The hypogen algorithm also calculates the cost of a null hypothesis that assumes no relationship in the data, and the experimental activities are normally distributed about their mean. Accordingly, the greater the difference (∆cost) between the total and the null costs, it is more likely that the hypothesis does not reflect a chance correlation.
Fischer's randomization test
The Fischer's randomization test was used to ensure strong correlation between the chemical structures and the biological activity of the training set molecule. In this method, the biological activity was scrambled and assigned new values. Thereafter, the pharmacophore hypotheses were generated using the same features and parameters as those used to develop the original pharmacophore hypotheses. If the randomization run generates better correlation coefficient and/or better statistical parameters than the original hypothesis may be considered to be developed by chance. Depending upon the statistical significance randomization run produces a different number of spreadsheets. The statistical significance is given by following equation.
Where, a defined as total number of hypotheses having a total cost lower than best significant hypothesis, whereas b denoted by total number of HypoGen runs and random runs. In case of 95% confidence level 19 random spreadsheet are generated (b = 20) and every generated spreadsheet is submitted to HypoGen using the same experimental conditions as the initial run. In the present study, the developed pharmacophore model was checked at 95% confidence level and produced 19 spreadsheets.
Test set prediction
The prediction of the test set compound is a crucial step in order to verify whether the pharmacophore model was able to accurately predict the activities of compound beyond the training set molecule. Consequently, in the present research 99 test compounds were predicted using the developed pharmacophore model by Ligand Pharmacophore Mapping protocol in DS, depicted in 
Virtual screening
Virtual screening is a vital technique which is used to identify novel potent compounds that can repress or trigger the activity of a particular target. In this work, the best developed pharmacophore model was considered for 3D query in the NCI (National Cancer Institute) database screening to retrieve the novel scaffold for HIV protease inhibitors. The NCI database contains 265,242
compounds. The filtered compounds were screened with a number of criteria. The flow diagram of the screening protocol is given in the Figure 2 . Biological activity (K i ) of the retrieved compounds was estimated using the pharmacophore model and only those compounds whose activity falls within range of the training set compounds were selected for next step. Further the compounds were fitted in the pharmacophore model using maximum omitted feature set to '0'. Lipinski's rule of five [56] was applied and then molecular docking was performed. The dock score and binding energy of the compounds were compared with most active compound of the dataset. Finally the binding interactions were observed between the potential HIV-protease compounds and catalytic residues of the active site. 
Molecular docking
In order to understand how the screened drug-like virtual hits bind to the receptor, potential HIVprotease ligands were analysed using the ligand-receptor interactions by molecular docking.
Molecular docking is one of the best filtering methods and a crucial technique in drug design process. The LigandFit protocol of the DS was used to dock the retrieved compounds by virtual screening. The LigandFit protocol first detects the cavity to identify and select the region of the protein as the active site, and secondly dock the ligands to the selected site. 3D regular grids of points are employed for site detection and also for estimating the interaction energy of the ligand with the protein during docking. The protein receptor of the HIV protease was selected from RCSB Protein Data Bank (RCSB-PDB) for the molecular docking study. Among several HIV protease inhibitors PDB ID: 1T3R was selected based on the receptor size, resolution and deposited date.
Both receptor and ligands were prepared using standard tools Prepare Protein and Prepare Ligand of DS respectively. Both protein and ligand were minimized using CHARMm force field. The 'Build Loop' and 'Protonate' parameters were set to 'True' while, dielectric constant, pH, ionic strengths and energy cut-off were considered as default value for the protein preparation. In case of ligand preparation 'Change ionization', 'Generate Tautomers' and 'Generate isomers' were set to 'False', and 'Generate Coordinates' was set to '3D'. The binding site was identified after protein preparation based on the volume occupied by the ligand in protein-ligand complex. The validation of docking protocol is essential to avoid the false positive results of molecular docking. In order to validate docking parameters, the co-crystal from PDB was initially sketched and docked into the active site HIV protease. The docked pose was checked to see whether it was able to produce the hydrogen-bonding interactions with the critical amino acids. The RMSD between the docked pose and the co-crystal was calculated to determine if the docking parameters were able to reproduce a conformation comparable to that of the co-crystal at the active site of HIV protease. Then the potential molecules were docked using the same parameters as in the co-crystal docking. During the docking process, the top ten conformations for each ligand based on the dock score after energy minimization using the smart minimizer method (which begins with the steepest descent method and is followed by the conjugate gradient method) were assessed. The docked poses were validated based on the hydrogen-bonding interactions between the candidate molecules and the active site residues.
Results and discussion
The pharmacophore model was developed based on training set (n tr = 30) compounds by the was confirmed by Debnath's method [31, 57] . A valid hypothesis should have the overall cost of the hypothesis far from the null cost and close to the fixed cost. It is elicited that the difference in cost (∆cost) is the difference between the null cost and the total cost of the hypothesis; a cost difference of 40-60 bits leads to a predictive correlation probability of 75-90%, and if the difference is greater than 60 bits, the hypothesis is considered to have a correlation probability of greater than 90% [58] .
In the current study the cost difference for Hypo1 (Table 1 ) was found to be 78.524 that is more than 60 bits, indicating that this hypothesis has a >90% chance of being able to select HIV inhibitors. Table 2 ) mapped with most active compound of the dataset suggested that hydroxyl group present in the molecule behaved as HBD, whereas oxy group attached to sulphur atom revealed as HBA. The bulky group, iso-butane present in the molecular scaffold imparted the hydrophobicity of the molecule. The phenyl ring was critical for the aromatic ring features. The best selected hypothesis was validated to nullify over prediction of the bioactivity for inactive compounds through hyporefine. In this process, the steric interaction of the compounds was considered in hypothesis generation, but this factor was not portrayed in the validated (refine)
hypothesis. This indicated the presence of steric hindrance of the molecule has not direct influence on inhibitory constant to HIV protease. Therefore it can be postulated that to design or synthesize new chemical entities of HIV-protease inhibitors HBA, HBD, H and R factors with critical interfeature distances (Figure 3b )are to be crucial factors. 
Test set prediction
The robust model should have the capability to predict the activities of the compounds which were not involved in model generation. Altogether, 99 compounds (Table S1 in supplementary file and 
Fischer randomization test
The Fischer randomization test was used to check the statistical relevance of the hypothesis of interest by assigning a particular confidence level. In the present case confidence level was set to 95%, so 19 random spreadsheets were created by shuffling the experimental activity values of the training set compounds, and a hypothesis was generated for each spreadsheet. The significance of the hypothesis was calculated as per equation (1). The correlation of 19 spreadsheets is depicted in the Table 3 which indicates that none of the values generated after randomization produced hypotheses that exhibited predictive powers similar to that of hypo 1 ( Table 1) . The average of correlation coefficient for all 19 trials was about 0.772. It was also observed that the total costs of randomized runs were much higher than the total cost of Hypo 1. The total cost of Hypo 1 and all other 19 random hypotheses is depicted in the Figure 5 and Table 3 . The above discussion clearly shows that the selected pharmacophore model was not generated by chance. 
Virtual screening
Virtual screening is the powerful technique for potent molecules identification and an effective alternative to high-throughput screening methodologies. The validated QSAR, pharmacophore or molecular docking models are used to screen the molecular database for lead discovery. In the present research, pharmacophore model (Hypo 1 in Table 1 ) was used to search the NCI database Mapping protocol of DS. It was found that 1268 compounds were in the range of activity 0.008nM to 238.700nM, which is the range of activity of training set molecules. These were further considered for screening. These compounds fitted with Hypo 1 using omitted feature set to '0' and it was observed that 1241 compound successfully fitted with all the features but 27 compounds failed to map all pharmacophoric features. These molecules were further considered to check
Lipinski's rule of five [56] and observed that 493 compounds failed to pass the rule. The remaining 748 compounds were considered for molecular docking study using the LigandFit module of DS, where 710 compounds were successfully docked. The most active compound of the training set was also docked and binding energy calculated along with docked 710 compounds. DockScore of 10 molecules out of 710 were found to be greater than DockScore of most active compounds. Among 
Molecular docking
The molecular docking is used in order to find out the accurate and preferred orientations of the ligand at the active site of the protein. The docked complexes of the potential HIV-protease ligands screened from NCI database ( Figure 6 ) and most active compound (H11 in Figure 1 ) of the training set were considered to assess the optimal orientation and binding abilities. The crystal structure of HIV protease (PDB ID: 1T3R) was collected from RCSB-Protein Data Bank. Self-docking is one of the approaches to validate the molecular docking method [59] in which bound ligand is docked at the catalytic site of protein molecule and the conformer of the original bound ligand is superimposed to the docked poses to calculate root mean square deviation (RMSD) values. It is reported that low RMSD (<2 Å) value of original bound ligand validates the docking procedure [59] .
In the present study, self-docking approach was considered to validate the docking procedure. In this approach the freshly docked complex of bound compound with the receptor was superimposed with original complex downloaded from RCSB PDB (PDB ID: 1T3R). The RMSD values was found 0.00Å, which indicated that the protocol was selected in the docking method was validated. 
Conclusion
The work presented here was performed to achieve the structural and orientational factors important for HIV protease inhibitors, to focus on the pharmacophore-based virtual screening of molecular database and propose the potential HIV-protease compounds for the anti-HIV agents. A number of hypotheses were generated based on 30 training set compounds and finally ten hypotheses were retained for further evaluation. Based on Debnath's analysis, Fischer's randomization test, test set prediction and Roy's r 2 m prediction the Hypo 1 was selected as best pharmacophore model. This model was suggested that one of each HBA, HBD, H and R features were crucial for inhibitory activity. The Hypo 1 was selected to for the virtual screening of NCI database to retrieve some potential and less toxic anti-HIV agents. Initial screened compounds were passed through several criteria including the range of activity of training set, fit to model with omitted feature set to '0'and comparison of dock score and binding energy with most active compound of the data set to reach the potential compounds. Among the more than twenty five thousand initial hit compounds, seven compounds finally satisfied all these criteria and were used to further evaluate the binding interactions with critical amino residues at the active site of HIV protease. This virtual screening using the Hypo 1 obtained one potential molecule, NCS70804 from NCI database which is already confirmed as active in anti-HIV screening. A number of hydrogen bonds and bump interactions were observed between potential HIV-protease compounds and catalytic residues such as Leu24, Asp25, Thr26, Gly27, Asp29, Ile50 and Ile84. Therefore this indirect receptor-independent pharmacophore model can calculate accurately the position and orientation of potential ligand in a binding site and the selected model has enough potential to retrieve the active molecule from database. The potential HIV-protease molecules will be subjected to experimental validation to obtain further confirmation. 
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